A comparative study measuring effectiveness of tofacitinib ointment and betamethasone valerate ointment to cure alopecia areata.

A comparative study evaluating the efficacy of topical tofacitinib versus topical betamethasone valerate in treatment of alopecia areata in a tertiary care hospital of eastern India. - NIL

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2024/07/070905

Enrollment

Registered

2024-07-19

Start date

Unknown

Completion date

Unknown

Last updated

2024-08-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L989- Disorder of the skin and subcutaneous tissue, unspecified

Interventions

Intervention1: Topical tofacitinib 2% ointment: Intervention Details: Dose:2% tofacitinib ointment, Frequency: Twice daily, continuously for total period. Route of administration: Topical application

Eligibility

Inclusion criteria

Inclusion criteria: Patients giving consent All clinically diagnosed cases of alopecia areata Not taken treatment of alopecia areata for last 1 month prior to enrolment

Exclusion criteria

Exclusion criteria: Pregnant and Lactating women Patient taking immunosuppressive therapy. Alopecia areata only of eyelash

Design outcomes

Primary

Measure	Time frame
improvement in hair lossTimepoint: 6 months	—

Secondary

Measure	Time frame
Adverse Effect Tolerability Quality of lifeTimepoint: 6 months	—

Countries

India

Contacts

Public ContactArghyaprasun Ghosh

Bankura Sammilani Medical College

arghyap_ghosh@yahoo.com9432443277

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026